Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Aurobindo Pharma gets...

    Aurobindo Pharma gets USFDA nod for Levofloxacin injection

    Written by savita thakur thakur Published On 2016-02-12T08:15:19+05:30  |  Updated On 12 Feb 2016 8:15 AM IST
    New Delhi: Aurobindo Pharma said it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Levofloxacin injection, an anti-infective used in the treatment of bacterial infection in adults.

    The approval is for Levofloxacin in 5 per cent Dextrose injection in the strengths of 250 mg/50 ml, 500 mg/100 ml, and 750 mg/150 ml, single use containers, Aurobindo Pharma said in a BSE filing.

    The product is expected to be launched in the first quarter of 2016-17, it added.

    The approved product is bio-equivalent and therapeutically equivalent to the reference listed drug product (RLD) Levaquin (Levaquin in 5 per cent Dextrose) by Janssen Pharmaceuticals, Inc.

    It has an estimated market size of USD 46 million for the twelve months ending December 2015 according to IMS, the company said.

    Levaquinis is used to treat bacterial infections that cause bronchitis or pneumonia and to treat people who have been exposed to anthrax or plague.

    This approval is the 25th ANDA (including two tentative approvals) to be approved out of Unit-IV formulation facility in Hyderabad, India, used for manufacturing general injectable products.

    Aurobindo Pharma's product range cover over six major therapeutic/product areas encompassing antibiotics, anti-retrovirals, CVS, CNS, gastroenterologicals and Anti-Allergies. It is marketing these products globally in over 150 countries.
    Aurobindo Pharmabacterial infectionbacterial infection drugbacterial infection in adultslevofloxacinLevofloxacin injectionUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok